Listed life sciences business secures deal for product to be used in Japan
A York-based business developing compounds to tackle obesity, cardiovascular disease and diabetes has signed a deal for one of its products to be used in cardiovascular food supplements in Japan.
OptiBiotix Health today announced that its fully-owned subsidiary, ProBiotix Health, has reached a non-exclusive license agreement with Tenshindo Co for the use of Lactobacillus plantarum LPLDL®.
Tenshindo is a manufacturer of functional food and cosmetics products, and was founded in Japan in 1986.
LPLDL® will be the active ingredient in a novel cardiovascular health product that Tenshindo will add to its current portfolio of over 50 products.
Tenshindo and ProBiotix will work together to obtain an authorised cardiovascular health claim for LPLDL® from the Japanese authorities, based on existing clinical and market evidence.
This is the first end product application deal in Japan emerging from ProBiotix’s agreement with the local distributor EIWA Trading Corporation in February 2019 to distribute LPLDL® in the country.
It is also part of the company’s strategy to include LPLDL® in a range of cardiovascular health supplements, and in food, dairy, and beverage products across the world.
EIWA and ProBiotix are now working to replicate this model with different partners and different applications in the Japanese market.
Dr Luis Gosalbez, Business Development Director of OptiBiotix, said: “We are pleased to announce this deal with Tenshindo, which will mean our first LPLDL® finished product placement on the Japanese market.
“Obtaining an authorised cardiovascular health claim for LPLDL® from Japanese authorities will not only be highly advantageous from the commercial point of view, but also an important endorsement for ProBiotix’s science.
“Tenshindo, with over 30 years of experience in this market, are an excellent commercial and regulatory partner to make the most of this opportunity.”
